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ABSTRACT 
Two groups of New Zealand white rabbits were injected with 
homogenate3 from Tumorous-head (Tuh) and Wild-type (WT) Drosophila 
melanogaster. A third group was used as a saline injected control. 
Blood collected in both acute and chronic studies was subjected to 
various hematological and post mortem studies. 
The Tuh injected group showed a five-fold increase in throm-
bocytes (blood platelets) over the controls and a four-fold increase 
over the wild-type group. Reduced clotting times were noted from 
acute to chronic studies in both tumorous and wild-type studies; 
however, the magnitude of change between the two groups was insig-
nificant. Investigations involving electrophoretic banding pat-
terns, differential blood cell counts, and comparative hematocrits, 
provided less significant results. 
The author concludes that the reduced clotting times reported 
in tumorous-head injected rabbits represent a decrease in bleeding 
time. This was caused by the more effective plugging of the damaged 
vessel by the increased number of platelets. 
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INTRODUCTION 
The term hemophilia is loosely applied to several hereditary 
deficiencies of coagulation, all of which cause bleeding tendencies 
hardly distinguishable from one another. Regar'dless of the precise 
type of hemophilia, transfusion of normal fresh plasma or of the 
appropriate purified protein clotting factor into the hemophilic 
person usually relieves his bleeding tendency for a few days (1). 
The present study involves the relative effects of several antigens 
on the hemostatic mechanism and, therefore, warrants an expanded 
discussion of hemostasis. 
Wnen the walls of blood vessels are severed, the subsequent 
blood loss is reduced by a sequence of reactions known collectively 
as hemostasis. There are three major facets of hemostasis: vascu-
lar spasm, the formation of platelet plugs, and plasma coagulation 
(1). 
The nervous reflexes are presumably initiated by pain impul-
ses originating from the traumatized vessel or from nearby tissues. 
The reflex signal travels first to the spinal cord, then back through 
the sympathetic nerves causing spasms which extend several centi-
meters in either direction from the point of rupture. The reaction 
lasts between a few seconds to a few minutes. Most spasms probably 
result from local myogenic contractions of vessels initiated by dir-
ect damage to the vascular wall (1). Compared to our knowledge 
1 
2 
about the coagulation mechanism, 1ittle is known about the role of 
the vasculature in hemostasis (2). Zucker (3), Chen & Tsai (4), and 
Bernan & Fulton (5) believed that the rate of blood flow through a 
vessel influences the local concentration of precoagulants in the 
blood. Increased flow rate would reduce the local precoagulant 
concentration whereas decreased flow rate would further enhance this 
concentration. Vasocontriction with consequent decreased blood flow 
would, therefore, be expected to be beneficial to the hemostatic 
process. Zucker {3,6) maintained that vasoconstriction involves not 
only the injured vessel but also others in the immediate vicinity, 
apparently because of the platelets' rele?se of serotonin, a vasocon-
strictor substance. Although vasoconstriction is inadequate to 
effect hemostasis, it has been suggested that the vasoconstrictor 
effects of serotonin may contribute to the process. 
Williams (2) reported that the activation of the Hageman Factor 
{Coagulation Factor XII) may possibly contribute to hemostasis by 
initiating the reactions of blood coagulation and by the production 
of peptides which are able to increase capillary permeability and 
smooth muscle contraction. Platelets may also release substances 
that increase capillary permeability {7). Increased capillary per-
meability may improve hemostasis by increasing the viscosity of blood 
within the vessels (8). Active vasoconstriction plays no role in 
hemostasis in nonmuscular vessels such as capillaries and some ven-
ules. Blood flow in these vessels may be retarded by local tissue 
pressure, by adhesion of endothelial or connective tissue elements, 
3 
or by arteriolar constriction (3,4,5). 
According to Williams (2), the vascular endothelium provides 
an inert surface for the reactions of blood coagulation and platelet 
aggregation. The smoothness of the endothelium, along with presence 
of its monomolecular layer of negatively charged proteins, prevent 
contact activation of the intrinsic clotting system by repelling 
platelets and other clotting factors. Damage to the endothelial 
surface causes loss of smoothness and negative electrical charge. 
This is believed to help activate Factor XII, thus initiating the 
intrinsic pathway of clotting. Sawyer (9) observed that electrical 
currents within and across the vessel wall may help to initiate 
irreversible clumping of the platelets, followed by their adhesion 
to the injury site. 
Astrup and Buluk (10) and Kirk (11) indicated that the endo-
thelium of blood vessels is rich in thromboplastic activity. This 
appears to be tissue thromboplastin (Coagulation Factor III). Tis-
sue Factor III reacts with Factor VII and calcium to form a complex 
to initiate reactions to the extrinsic pathway of blood coagulation 
and leads to rapid formation of thrombin (figure 2). Thombin may 
then also effect platelet aggregation, or fibrin formation, and thus 
accelerate the reactions of hemostasis. 
The intima of blood vessels contain significant quantities of 
plasminogen activator which may be released at the injury site and 
act as a protective mechanism against excessive local fibrin forma-
tion (2). 
4 
Guyton (1) describes the formation of the platelet plug as the 
second hemostasis event. This is the action by the platelets to 
close the vessel's trauma site. An understanding of this phenomenon 
-
warrants an explanation of the nature of platelets themselves. 
Platelets, or thrombocytes, are minute round or oval discs about 
2 microns in diameter and are derived from the cytoplasm of megakary-
ocytes, large immature cells in the bone marrow (1). After matura-
tion, these cells fragment into cytoplasmic clumps which are released 
into the peripheral circulation as functional platelets (12). Each 
megakaryocyte is capable of producing 3,000 to 4,000 platelets (13), 
but the number produced and released in the bone marrow is regulated 
by the number already in circulation (14). In man, the normal plasma 
concentration of platelets ranges from 150,000 to 450,000 per cubic 
millimeter while their life span is approximately ten days, with a 
half-life of three days (12). 
White (15) suggests that a platelet can be divided into three 
structural areas or zones, each zone being involved in a specific 
function. These are the peripheral zones, the sol-gel zone, and the 
organelle zone. 
The peripheral zone is involved in adhesion and aggregation. 
It separates the platelet from its surrounding medium and is composed 
of an exterior coat, a membrane, and submembrane filaments. The 
exterior coat is an amorphous substance, rich in mucopolysaccha-
rides and glycoprotein. Clottino factors identical to those present ~ 
in the plasma are present. The membrane just below the exterior coat 
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is the source of platelet Factor 3 (PF3), a phospholipid which 
becomes available on the surface of the platelet during irreversible 
aggregation. PF3 interacts with some clotting factors in the intrin-
sic pathway to produce fibrin. 
The sol-gel zone provides support for cell structure and mech-
anisms for cell contraction. The peripheral zone and the sol-zone 
share submembrane filaments. The submembrane filaments, along with 
microtubules and microfilaments in the sol-gel zone, help to support 
the shape of unaltered platelets and, in response to stimuli, help in 
the extension and stabilization of pseudopod formation. They also 
participate in the contractile process during irreversible aggrega-
tion and retraction. The microfilaments are the source of the con-
tractile protein, thrombosthenin. 
The organelle zone, which consists of organelles randomly dis-
tributed throughout the cytoplasm is concerned with respiratory, 
excretory and production functions, as well as storage and release of 
energy. It also regulates the platelet's chemical and physiologic 
response to stimuli. 
Williams {2) observed that platelets undergo three changes dur-
ing hemostasis: adhesion {aggregation), contraction, and secretion 
{releasing reaction). Adhesion is an independent facet in platelet 
physiology, because adhesion can occur without contraction. Secre-
tion is dependent on the contractile system of platelets; hence, it 
cannot occur alone. Contraction can develop up to a point without 
secretion. The contractile mechanism in platelets consists of the 
6 
fusion of centrally clumped organelles and the selective release of 
several endogenous components that aid in hemostasis. 
Platelets respond to vascular trauma by drastic reorganization 
of both their internal and surface structure (15). When they come in 
contact with a wettable surface, such as the subendothelial collagen 
fibers in the vascular wall, the following changes occur: they begin 
to swell (1); the submembrane filaments and microtubules form a con-
strictive band around the platelet organelles; the centrally located 
organelles fuse (15); they assume irregular forms with numerous 
irradiating processes protruding from their surfaces (1); the exter-
ior coat acquires adhesive qualities causing the platelets to adhere 
to the collagen fibers at the damaged vessel site. Subsequently, 
release of certain chemical constituents occurs. These constituents 
are usually bound to the membrane surfaces and may participate in 
clotting by providing acceleratory influences. Several of these 
activities have been designated as platelet factors 1 to 4 (2). 
Platelet factor 1 is plasma coagulation factor V adsorbed by the 
platelets (16). Platelet factor 2 is a protein which accelerates 
the clotting of fibrinogen by thrombin, aggregates platelets from 
platelet-rich plasma further potentiating the piatelet aggregating 
effect of ADP (17), and counteracts the inhibitory effects of plasma 
antithrombin III on a thrombin-induced fibrinogen~fibrin reaction. 
Platelet factor 3 or 4 are both influenced by aggregation {18,19, 
20). Platelet factor 3, a lipoprotein component of platelet membrane, 
becomes available to coagulant enzymes and cofactors of plasma 
7 
following platelet aggregation or platelet trauma (21 ,22,23). The 
active component is the phospholipid moiety bound to both membranes 
and granules which accelerates plasma clotting, probably by acting as 
a surface catalyst (23). The lipid membrane is more readily exposed 
for participation in clotting (24). Activation occurs because the 
soluble enzymes are provided a surface on which to act, thus, having 
the effect of concentrating the enzymes in a localized area, leading 
to faster reaction rates (25). Phospholipids accelerate blood coagu-
lation by participating in the reactions involving factor VIII and 
those involving factor V. Little activity can develop even when the 
release reaction does not occur (26,27). Platelet factor 4 is a gly-
coprotein (28) released from platelets following platelet aggregat-
ing by ADP, thrombin, or epinephrine (29-31). It shortens the 
thrombin clotting time in the presence of heparin (29-32), potenti-
ates ADP-induced aggregation in vitro, precipitates fibrinogen, non-
enzymatically clots soluble fibrin monomer complexes (24), and neu-
tralizes certain fibrinogen breakdown products (antithrombin VI) (33). 
Platelets also contain intracellular fibrinogen (34-37) which appear 
not to be derived from plasma fibrinogen and may be synthesized in 
the megakarycyte (37). As indicated previously, some other constitu-
ents released by platelets are serotonin, adenosine triphosphate 
(ATP), and large quantities of adenosine diphosphate (ADP) (15). 
The ADP aids in activating nearby platelets causing them to adhere 
to the originally activated platelets. Therefore, at any vascular 
trauma site the exposed subendothial collagen elicits a continuous 
8 
cycle activating successively increasing numbers of platelets accumu-
lating in the formation of the hemostatic platelet plug. This is a 
fairly loose plug; however, the blocking of blood loss is usually 
successful. During the process of blood coagulation, thrombin is 
formed. It further alters the platelets to irreversible aggregation, 
thus forming a tight and unyielding plug. In performing the usual 
coagulation tests one generally deals with the concentrations of fac-
tors present in plasma at normal or less than normal concentrations. 
Under certain conditions the platelet concentration may be important 
as well. Excessive platelet concentrations is a condition called 
thrombocytosis. Depending on the effectiveness of hemostatic or 
thromboplastic functions of this condition, a reduced bleeding time 
or clotting time may possibly result. Transitory thrombocytosis may 
result from the mobilization of extravascular platelet pools, for 
example, following epinephrine administration (38) or vigorous 
exercise (39). All other forms of thrombocytosis apparently are 
the result of accelerated platelet production. Preliminary thrombo-
kinetic data would suggest that this may result from two different 
mechanisms (Table 1). In individuals with reactive or secondary 
thrombocytosis, the platelet count is directly col'related with the 
megakaryocyte mass and is inversely correlated with the mean megaka-
ryocyte volume. This is the result of regulatory processes that nor-
mally reduce the stimulus to nuclear endoredupl~cation as the plate-
let count rises (40,41). A direct and linear relationship between 
platelet turnover rate and total megakaryocyte mass has been 
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Table 1 
Thrombocytosis (2) 
A. Primary Jautonomous) 
1. Essential thrombocythemia 
2. Other myeloproliferative disorders 
B. Secondary (Y'eactive} 
1 . Chronic inflammatory disorders 
2. Acute inflammatory disorders 
3. Acute hemorrhage 
4. Iron deficiency 
5. Hemolytic anemia 
6. Malignant disease 
7. Postoperative 
8. Response to drugs 
9. Response to exercise 
10 
demonstrated {40,41}. The factors leading to accelerated platelet 
production in the various disorders associated with reactive throm-
bocytosis are almost totally obscure. The principal importance of 
this disorder is the recognition of its benign nature and its differ-
entiation from autonomous thrombocytosis. 
In autonomous thrombocytosis, platelet production apparently is 
unresponsive to normal regulatory processes; and the platelet count 
does not correlate with the megakaryocyte volume as seen in Table 2 
{40}. The uecrease in megakaryocyte size normally resulting from 
an increase in the circulating platelet mass is absent. Autonomous 
thrombocytosis has been likened to neoplastic proliferation of other 
hematopoietic elements {42). 
The megakaryocyte-thrombocyte system has been shown to respond 
to thrmbocytopenia and thrombocytosis by respectively increasing and 
decreasing platelet production {43,44,45}. These responses have been 
shown to be humorally mediated {46,47). While almost nothing is 
established about thrombopoietin, it is known to affect both the num-
ber of magekaryocytes found within the marrow and their proliferative 
behavior {47). With stimulation, there is an increase in the rate of 
maturation of the megakarocyte size resulting from an increase in 
the number of mitosis within the individual cells, and possibly an 
increase in the size of thrombocytes appearing in circulation. With 
suppression, megakarocytes are smaller and contain a decreased number 
of nuclei. The changes affect the number of platelets produced per 
megakaryocyte. An inverse relationship is also normally found between 
11 
Table 2 
Differentiation of Reactive and Autonomous Thrombocytosis 
Reactive Autonomous 
Thrombocytosis Thrombocytosis (secondary) 
THROMBOKINETIC FEATURES 
Total megakaryocyte 
mass Slightly increased 
Megakaryocyte number Increased 
Megakaryocyte volume Decreased 
Platelet turnover or 
production rate Increased 
Total platelet mass Increased 
Platelet survival Normal 
CLINICAL AND LABORATORY FEATURES 
Thromboembolism and hemorrhage Uncommon 
Duration Often transitory 
Splenomegaly Absent* 
Platelet count Usually> 
400,000/mm3 
Bleeding time Usually norma 1 
Platelet morphology and 
Usually normal function 
Leukocyte count Usually normal 
*Unless as the result of the underlying disorder. 
Thrombokinetic data from Harker (40). 
(primary) 
Greatly 
increased 
Increased 
Increased 
Increased 
Increased 
Normal to 
slightly 
increased 
Common 
Usually~ 
persistent 
80% of cases 
Usually> 
1 ,000,000/mm3 
Often 
prolonged 
Often abnormal 
Increased in 
90% of cases 
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the number of thrombocytes in circulation and in the size of megakary-
ocytes within the marrow (40). In the thrombocytosis accompanying 
inflammatory states and iron deficiency, however, there is dissoci-
ation between increased megakaryocyte number and the number of throm-
bocytes produced per megakaryocyte. At the present time, it is impos-
sible to say whether megakaryocyte stimulation is mediated by one or 
more stimulating factors. 
Studies of cyclic variations in the platelet count in normal 
individuals and in individuals with cyclic thrombocytopenia and tidal 
platelet disgenesis, suggest that the control of thrombopoiesis 
involves a negative "feedback" mechanism that contains a time delay. 
A result of the time lag may magnify perturbations of either a posi-
tive or negative nature, resulting in an oscillation of platelet pro-
duction. More than one humoral regulation, or a combination of nega-
tive and positive feedback regulatory process, may be involved (4g). 
Accelerated thrombopoiesis commonly is associated with acceler-
ated erythroopoiesis. Thus, increased platelet numbers are present 
in subjects with various hemolytic anemia (49), following acute blood 
loss ( 50,51,52) , and in some subjects with secondary polycythemia 
associated with renal tumors ~ 53). The association of thrombocyto-
sis with various neoplasms has been recognized for many years (52). 
Platelet counts in excess of 400,000/mm3 may be found in a large pro-
portion of individuals with neoplasms, in as many as 40 percent of 
cases in one study (54). The persistence of post-splenectomy throm-
bocytosis in anemic subjects has been found. Despite the evidence 
13 
that thrombopoietin and erythropoietin are different substances (55), 
these findings suggest that there is some interrelationship between 
erythropoietic and thrombopoieti: control mechanisms (56). 
Several interdependent coagulation factors enter into reactions 
that initiate clotting (see Table 3). The deficiency of any factor 
may result in an abnormal hemostatic response. Any increase in fac-
tor concentration, in association with changes in the rate of blood 
flow, may lead to thrombus formation (2). 
In 1904, Morawitz presented the classical Theory of Blood 
Coagulation. He postulated that: 
a) prothrombin, calcium, and fibrinogen were present in 
circulating blood. 
b blood remained fluid in the absence of thromboplastic 
factor which he called 11 Thomboplastin .. or "Thrombo-
kinase." 
c) thromboplastic factor resulted from tissue injury or 
platelet disintegration. 
d) thromboplastic factor could convert prothrombin into 
thrombin with subsequent fibrin formation. (12) 
Many research workers in the field of blood coagulation refer 
to Morawitz•s thromboplastic factor or thromboplastin as prothrombin 
activator. Unfortunately, the detailed mechanisms of prothrombin 
activator formation are still not clear. However, there is much 
better understanding of the mechanisms of prothrombin conversion to 
thrombin and action of thrombin to cause fibrin thread formation. 
Guyton (1) indicated that this causes the polymerization of fibrinogen 
molecules into fibrin threads within 10 to 15 seconds. The rate 
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limiting factor in causing blood coagulation is usually the formation 
of prothrombin activator and not the subsequent reactions beyond that 
point. The reactions in figure 1 are a modified illustration of 
Morawitz's postulate demonstrating the conversion of prothrombin 
to thrombin under the influence of prothrombin activator and calcium 
ions. 
Prothrombin 
Extrinsic ~ 
or 
Intrinsic~ 
Prothrombin 
Activator 
Thrombin 
Ca 
Fibrinogen-------- Fibrin Monomer 
Fibrin stabilizing factor 
Fibrin Threads 
Figure 1. r~orawitz's classical theory of blood 
coagulation 
As previously indicated,the rate of formation of thrombin 
from prothrombin is almost directly proportional to the quantity of 
prothrombin activator available. This in turn is approximately pro-
portional to the degree of trauma to the vessel wall or blood. In 
turn, the rapidity of the clotting process is proportional to the 
quantity of thrombin formed. 
Guyton (1) further described the action of thrombin on fibrinogen 
1.7 
to form a molecule of fibrin monomer. He noted that as several 
fibrin monomer molecules polymerize within seconds into long fibrin 
threads, they form the reticulum of the clot. In the early stages of 
this polymerization, the fibrin monomer molecules attach to one 
a~other by loose hydrogen and hydrophobic bonds, forming weak polymer 
chains. However, immediately thereafter, another plasma globulin 
factor, the fibrin stabilizing factor, acts as an enzyme to cause 
covalent bonding between the fibrin monomer molecules and also 
between the adjaGent polymer chains. Williams (2) noted this factor 
as catalyzing the formation of peptide bonds between glutamic acid 
and lysine groups in adjacent molecules of fibrin monomers in the 
clot. This adds tremendously to the three dimensional meshwork of 
the f~brin threads and yields a mechanically strong, hemostatically 
e fective c1ot. 
Two types of prothrombin activator resulting from two avenues 
of coagulation have been postulated (1): 
1. Tissue extract called the extrinsic pathway 
2. Plasma thromboplastin called the intrinsic pathway 
The terms "intrinsic .. and 11 extrinsic 11 refer to clotting inside and 
outside the vasculat~ system, respectively. With respect to effective 
rates, the intrinsic system is relatively slower than the extrinsic 
system. In either case, the final common pathway is the conversion 
of prothrombin to thrombin. In both path\'lays a series of plasma pro-
teins, especially beta globulins, play major roles. These along with 
the factors previously discussed are called blood clotting factors (1). 
One of the more recent schemes devised to diagram the 
18 
coagulation process was the cascade or waterfall sequence illustrated 
by Davie, Ratnoff (58), and MacFarlane (59). This is based on the 
theory that the blood coagulation process is primarily a series of 
enzyme reactions. These reactions are subdivided into three 
stages (figure 2). 
Erslev and Gabuzda (60) describe the first phase of the intrin-
sic system as the surface activation of Factors XII and XI. The 
conversion of Factor XII to XIIa ("a" denotes activated form) seems 
to require prior complex formation with Factor XI, which in turn 
is c: .anged to X I a. Factor XI a then triggers coagulation by acti vat-
ing IX to IXa, a potent pracoagulant. A complex is then formed of 
Factors IXa and VIII with platelet phospholipid. The formation of the 
uFactor VIII complex .. is accelerated by the presence of small quanti-
ties of thrombin. This complex then converts Factor X to Xa, which 
bv itself has "prothrombinase .. activity. The rate of reaction, how-
e 'er, is markedly accelerated by the presence of Factor V and plate-
let phospholipid. 
The extrinsic system short circuits the first stage of the 
intrinsic system by directly activating Factor X through the forma-
tion of a complex between Factor VII and tissue thromboplastin, which 
is composed of phospholipid and protein (60). 
Calcium is required for most of the coagulation reactions, a 
point of considerable laboratory importance. In vitro, blood can be 
prevented from clotting by reducing the calcium ion concentration 
below the threshold level for the clotting, either by deionizing the 
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calcium by reacting it with substances such as citrate ion or by pre-
cipitating the calcium with substances such as the oxalate iron, both 
substances commonly used as anticoagulant in laboratory coagulation 
testing (1). However, it is virtually impossible for hypocalcemia 
to be of sufficient magnitude in vivo to cause abnormal bleeding. 
Whether activated forms of Factors V, VII, and VIII exist or whether 
their activity is mediated solely through complex formation with phos-
pholipid remains uncertain. As previously indicated, the thrombin 
formed as the end-product of this accelerating series of reactions, 
in addition to forming fibrin monomer and activating Factor XIII!, 
also engages in .. positive feedback .. by increasing platelet aggrega-
tion and promoting Factor VII complex formation. Modulating influ-
ences on the negative side come from enzyme antagonists in the plasma. 
The activated forms of the coagulation factors are cleared from the 
circulation rapidly, which is also of considerable importance in 
keeping the process of clot formation under physiologic control (60). 
Most of the tests of the clotting mechanism depend on the 
appearance of a fibrin clot in the test tube. Quick (62) believed 
that if he added calcium and a source of prothrombin activator to 
oxalated plasma, prothrombin would be the rate limiting component 
of the clotting reaction. This test not only measures prothrombin 
specificially, but also factors I, V, VII, and X as well (see figure 
3). 
The present investigation explores the hemostatic responses of 
rabbits to antigens from Wild-type and Tumorous head strains of fruit 
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flies. A recent immunological investigation (63) produced results 
which could provide additional insights in studies concerned with the 
future treatment of hereditary deficiencies in coagulation. That 
investigation involved the intramuscular injection of New Zealand 
White rabbits with emulsifications prepared from wild-type and 
tumorous-head Drosophila melanogaster. The Tumorous-head Drosophia 
is a mutant strain of fruit fly in which homoetic tumors are produced 
on the head region. These tumors may take the shape of leg append-
ages or abdominal, or genital tissue. The protocol of Weihe's (63) 
research consisted of 5 injections at 10-aay intervals. Following a 
six-week resting period, blood was collected by ear-vein laceration. 
During these collections, it was noted that the rabbits immunized 
with the tumerous-head flies showed decreased bleeding times and 
increased hemolysis in the serum relative to the rabbits immunized 
with wild-type flies. 
Necrotic tissue areas were observed at the injection sites in 
both rabbit groups. The group immunized against the wild-type anti-
gens possessed tissue that was diffuse and filled with a viscous, pus-
like substance at the injection sites. The tumerous-head injected 
group possessed more localized and indurated tissue at the injection 
sites (63}. 
This study involves the relative effectiveness of the clotting 
mechanism in rabbits following intramuscular injections of homogen-
ates from wild-type and tumourous-head Drosophila melanogaster 
compared with the saline injected controls. 
MATERIALS AND METHODS 
New Zealand white rabbits having an average weight of 4 pounds 
were used in both acute and chronic studies. Each study was sub-
divided into 3 groups: 
1. Tumorous-head injected 
2. Wild-Type injected 
3. Saline (Control) injected 
The following strains of Drosophila melanogaster were used in 
this study: 
1. a tumorous-head mutant strain obtained from Arizona 
State University, and symbolized Tu-h (ASU) 
2. laboratory wild-types, including Oregon R-C, Canton S, 
Swedish C, and Urbana S, obtained from California 
Institute of Technology and symbolized W-t. 
Experimental cultures were maintained at 25°C in one-half pint milk 
bottles on freshly prepared standard Drosophila medium containing corn-
meal-agar-dried yeast -sucrose-molasses with propionic acid added as 
a mold inhibitor (64). 
The tumorous-head fly suspensions were obtained by emulsifying 
100 male and 100 female flies in a tissue grinder containing 4 ml of 
0.9% saline solution. Therefore, a dose of 200 Tu-h flies was used 
per injection. Similarly, the wild-type suspensions were obtained 
by emulsifying 25 male and 25 female flies from each of the four 
strains of W-t Drosophila, totaling 200 flies per injection per rab-
bit, in the 4 ml saline solution. The control group was injected 
with 4 ml 0.9% saline solution per rabbit. All dosages were 
23 
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administered by intramuscular injections at the biceps femoris. 
Whole blood was collected from all rabbits 10 days after the 
first injection for the acute study. The chronic study consisted of 
a series of 5 injections at 10-day intervals with blood collection 
10 days after the final injection. The blood was obtained by ear-
vein laceration and mixed with sodium oxalate in siliconized test 
tubes. Approximately 10 ml of each sample was immediately centri-
fuged at 14,900 g for 20 minutes at -5 to 5+°C for plasma separation 
and isolation. The remainder was used for various hematological 
assays. 
The following parameters were examined on all blood types: 
1. Hematocrit 
2. Red blood cell count 
3. White blood cell count 
4. Platelet count 
5. Hemoglobin determination 
6. Prothrombin times (plasma) 
7. Electrophoresis (plasma) 
Hematocrit 
Red blood cell volume percentages were obtained from hemato-
crit values. They were determined by centrifuging blood in heparin-
ized capillary tubes and measuring the packed cell volumes on the 
critocap chart. 
Cell Counts 
Red blood cell, white blood cell, and platelet counts were 
done by coulter counter. Cells were diluted with Isoton at 1:50,000 
for RBc•s, 1:500 for wsc•s, and 1:3000 for platelets. All counts 
25 
were adjuste1 using the coulter counter coincidence correction chart. 
Hemoglobin Determination 
Hemoglebin concentrations were determined by hemoglobinometer 
(Coulter Electronics} and expressed in grams percent. The 1:50,000 
cell dilution utilized in the red blood cell count was again employed 
in this hemoglobin determination. 
Prothrombin Time 
Blood collection and plasma separation were accomplished as 
previously described. Plasma was promptly removed to another con-
tainer and stored prior to testing the same day. Reagents used were 
liquid activated raobit brain thromboplastin (prothrombin activator) 
and 0.02M calcium chloride. 
The experimental procedure followed for determination of pro-
thrombin times was published by Dade (65}. Equal quantities of 
activated thromboplastin and 0.02M calcium chloride were mixed and 
the resulting solution was pipetted in 0.2 ml aliquots into each of 
the desired number of 13 x 100 mm chemically clean test tubes. A 
small amount of test plasma was warmed at 37°C for one minute, fol-
lowed by forceful blowing of 0.1 ml of the test plamsa into the pre-
warmed activated thromboplastin-calcium chloride mixture. A timer, 
:alibrated in tenths of a second, was started simultaneously. The 
tube was quickly shaken and rotated so as to insure mixing. The 
appearance of the first fibrin web denoted the end point. 
26 
Post-Mortem Inspection 
All rabbits were sacrificed using sodium pentabarbital (Nembu-
tal) and autopsies conducted following the above examinations. The 
objective of these studies was two-fold: 1) general inspection of 
gross appearance of internal anatomy, and 2) general inspection of 
gross appearance of the injection sites. 
Special attention was given to organs concerned with the retic-
uloendothelial system--the liver and spleen. However, there was 
inspection of major organs of both thoracic and peritoneal cavities. 
InJection sites were examined for the reported localized, indurated 
necrosis versus the diffuse, viscous, purulent necrosis of the Tuh 
and riT specimens, respectively {63). 
Electrophoresis 
Plasma samples were diluted in a 1:10 ratio with 0.9% physio-
logical saline. It was found that better banding resolutions could 
be established with .02 ml plasma containing 70 mg/ml of protein 
activity. Polyacrylamide gel electrophoresis was carried out on a 
5.5~ gel prepared from the following solutions mixed per 100 ml of 
deionized water: 1) two parts solution I [14.0 grams acrylamide 
(Aldrich) to 0.4 grams N,N1--methylene-bisacrylamide (Isolab)], 
2) one part solution II [tri-borate buffer as described later], 
3) one part solution III [0.4 grams ammonium persulfate (J. T. 
Baker)] by volume. Added to the solution was .01 ml of N,N,N1,N1-
tetramethylethylenediamine. The solution was placed in 75 ml x 5 m 
ID x 8 mm O.D. electrophoresis tubes to polymerize. 
27 
A Buchler tube gel electrophoretic system was used with gel 
and chamber buffer composed of a tris-borate buffer. The buffer was 
composed of 2 20 boric acid, 4.31 g Tris (hydroxymethyl) aminomethane 
and 0.37 g EDTA terrasodium salt per 100 ml of distilled H2o. The 
chamber buffer was a 1:4 dilution of the stock gel buffer with a 
final pH of 8.6. One gram of ultrapure sucrose was added to the 20 
ml gel solution to eliminate mixing when water is layered over the 
surface. One-tenth grams of ultrapure sucrose was dissolved in 1 ml 
of plasma sample to facilitate layering on gel. Bromophenol blue 
was used as a marker to observe the migration on the sample. Gels 
were run at 30 milliamps for two hours at 25°C, and placed in 1% 
Coomassie blue (BB G-250)--trichloroacetic acid solution overnight. 
The required washing and destaining was done with 12.5% trichloro-
acetic acid, with changes performed periodically until the gel was 
clear. 
Statistical Analysis 
The animals were grouped according to the type of injection 
received, that is, the Control (saline), the Wild-Type (WT), or the 
Tumorous head (Tuh) injected rabbits. A study denotes the quantity 
of injections prior to assay, that is, acute Study (one injection) 
and chronic Study (five injections). The mean values of cell counts, 
prothrombin times, hernatocrits, and hemoglobin determination were 
subjected to unpaired "T" tests {Appendix 1) to determine significant 
changes between Groups (Control-WT-Tuh). Likewise, within each Study, 
analysis of variance was applied to determine significant changes in 
28 
the following categories {66): 
1) Between Groups, that is, acute and chronic Control groups 
(Category A) versus acute and chronic Wild-Type groups 
versus acute and Tumorous head groups. 
2) Within Groups, (Category B) 
3) Interactions, 
(Category AB) 
that is, acute Studies versus chronic 
Studies. 
that is, acute Control versus chronic 
Control-acute Wild-Type versus chronic 
Wild Type-acute Tumorous head versus 
chronic Tumorous head. 
Following post marten inspections, tissue samples from the liver, 
spleen, and injection site growths were provided for pathophysiologic 
analysis (67 ) . 
RESULTS 
The results of the prothrombin times are summarized in Table 4 
and figure 4. Mean values (X) are taken from both acute and chronic 
studies. The prothrombin times were measured in nine rabbits from 
each acute Study and eleven rabbits in each chronic Study. The 
analysis of variance revealed a significant decrease of 13.5% in the 
Within Groups category with an overall acute mean value of 9.12 sec-
onds compared to 7.89 seconds in the overall chronic study (Appendix 
2) . There were no significant changes in the Interaction and Between 
Group categories; however, significant time reductions were observed 
from acute to chronic means in both WT and Tuh Groups as revealed by 
tests (Table 5). 
The results of the hematocrits are indicated in Table 6 and 
figure 5. Hematocrits were taken from nine rabbits in each acute 
study and eleven rabbits in each chronic study. No significant 
changes were shown by analysis of variance. Significant differences 
were revealed between the chronic WT and chronic Tuh and between the 
acute Control and acute WT as shown by T tests in Table 5. However, 
the 1.1 % decrease from acute Control to acute Wild Type was very 
minimal. Mean values tended to remain close to the 39.28% Grand Mean 
of packed red blood cell volume. It is interesting to note a 5.2% 
increase in hematocrits from acute Tuh to the chronic Tuh (38.78 to 
40.78%) in the Interactions category. 
29 
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Table 4 
Maan Values of Prothrombin Times for Both Acute and Chronic Assays 
ACUTE ~HRONIC 
Animo ~ CONTROL r·~P~ TUMQROUS WIL~ 1UN,eROUS no. HEAD CONTROL TYP HEAD 
1 - - - 8.07 8.27 I 7.60 
2 . 9.20 9.91 8.30 - - -
I 
3 8.70 11.26 10.60 8.40 9.04 8.23 
4 9.24 11.00 8.85 9.13 9.02 8.68 
5 9.30 8.50 9.20 9.22 8.33 8.35 
6 8.82 8.50 8.60 7.55 8.25 6.97 
7 8. 31 8.05 8.07 7. 31 7.09 7.48 
8 8.31 8.28 8.23 8.18 7.74 7. 31 
9 8.i4 8.80 9.26 7.70 6.90 7.93 
10 9.38 9.10 8.33 7.44 8.00 6.98 
11 10.10 9.91 10.84 7. 51 I 7.40 6.82 
-X 8.99 9.27 9.10 8.16 8.18 7.70 
s .575 1. 20 1 .00 .745 .902 .641 
52 
.330 1. 41 1. 00 .556 .813 .411 
Mean values are recorded as time in seconds. T values showed signi-
ficant reductions from acute to chronic means in both WT and Tuh 
groups. 
Analysis of variance 5howed significant decreases of the overall acute 
mean to overall chronic mean. 
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8.99 
7.70 
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Figure 4. Changes in mean prothrombin times for 
Tuh, WT, and control animals in acute 
and chronic studies. 
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Table 6 
Mean Values of Hematocrits for Both Acute and Chronic Assays 
- ACUTE CHRONIC 
Anima l CONTROL '1~~-~ TUt.;\CROUS WILD TUMOROUS no. HEAD CONTROL TYPE H ~EAD 
1 - - - 42 40 40 
I I 
2 - - - 40 38 40 I 
3 40 36 40 39 38 41 
4 41 40 40 41 41 40 
5 40 39 37 40 40 42 
6 39 37 40 36 35 38 
7 42 39 40 41 38 43 
I 
I 8 40 40 40 38 38 38 
9 40 40 42 39 39 40 
10 40 38 35 38 41 45 
11 37 38 35 40 37 40 
-X I 39.88 38.55 38.77 39.45 38.63 40.63 
s 1. 4 1.4 I 2.5 1. i 1. 8 2.1 
52 2.0 2.0 6.2 2.9 3.3 4.3 
Mean values are recorded as cell percentage of whole blood. T value3 
demonstrated a significant decrease between acute control and acute 
Wild-Type and a significant increase from chronic Wild Type to chronic 
Tumorous head. Analysis of variance showed no significant changes. 
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Figure 5. Changes in mean hematocrits for Tuh, WT, and 
control animals in acute and chronic studies. 
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The results of the hemoglobin determination are shown in 
Table 7 and figure 6. Hemoglobin determinations were taken from six 
rabbits in each acute study and nine rabbits in each chronic study. 
There were significant changes in the Interactions category (Appendix 
2). These results showed a 12.0% decrease from the acute Controls 
to the chronic Controls (11.25 gm % to 9.90 gm %); an 11.0% increase 
from the acute WT to chronic WT (8.61 gm % to 9.63 gm %); and a 9.7% 
increase from the acute Tuh to the chronic Tuh (9.82 gm % to 10.77 gm 
~) . The T tests showed significant decreases of 23.5% and 12.7% in 
both acute WT and Tuh Groups, respectively, with respect to the Con-
trol. 
The results of erythrocyte counts are illustrated in Table 8 
and figure 7. Erythrocyte counts were taken from six rabbits in 
each acute study and nine rabbits in each chronic study. The Within 
Groups category showed a 36.0% elevation of the chronic study mean of 
5.97 x 1o6; mm3 compared to the acute mean of 4.39 x 106/mm3 (Appendix 
2). All categories indicated significant changes as shown by T 
tests (Table 5). The acute assays showed a 30 and 16.1 %decrease in 
the mean erythrocyte counts of Wild-type and Tuh groups, respectively, 
as compared with the Control. There were 20.5% more erythrocytes in 
the acute Tuh than the acute WT. Chronic assay values showed a 4.5% 
decrease in WT and a 15.4% increase for the Tuh injected group as 
compared with the Control, and a 20.8% increase for Tuh compared with 
WT rabbits. 
. 
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Table 7 
Mean Values of Hemoglobin Determination for Both 
Acute and Chronic Assavs 
-.-
ACUTE ~HRONIC 
Anjrc;~ l CONTROL t'~~~ ~UEMQ.RQ: IS EAD CONTROL flLD YPE TUM~ROUS HEA 
1 - I - - - - -
2 
- - - -
- -
3 - - - 7.50 8.70 7.40 
4 
- -I -
9.20 15.40 10.40 
5 
- - -
12.30 9.40 12.10 
6 10.40 9.20 9.16 8.00 9.30 8.75 
I 
7 12.20 I 7.70 11.50 11.10 10.90 10.60 
8 12.40 10.50 9.80 9.70 11.00 14.00 
9 11.05 I 6.90 11.05 10.40 8.90 12.10 
10 12.45 10.55 8.30 10.20 9.10 9.10 
11 9.00 6.80 9.10 10.00 8.60 10.10 
- 11.25 I 8. 61 9.82 9.82 10.14 10.51 
s 1.38 1. 75 1.23 1.47 2.16 2.01 
52 1. 90 3.06 1. 52 2.17 4.66 4.02 
Mean values are recorded as concentration in grams percent. T values 
indicated significant decreases in both acute Wild Type and Tumorous 
head with respect to the acute Control. Analysis of variance showed 
significant changes in the Interactions category. 
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Figure 6. Changes in mean hemoglobin concentrations for Tuh, 
WT, and control animals in acute and chronic studies. 
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Table 8 
Mean Values of Erythrocyte Count of Both Acute and Chronic Assays 
-
I ACUTE ~HRONIC 
An~ mol CONTROL WI~D TUMOROUS WILD TUMOROUS 10. TY E HEAD I CONTROL I TYPE HEAD_ 
1 - - - - - -
2 - - - - - -
I 
3 - - - 3,660,000 4,480,000 3,780,000 
4 4,445,000 5,360,000 5,400,000 
5 I 5,476,000 4,660,000 5,475,000 
6 5,500,000 3,340,000 ~,368,000 4,203,000 4,880.000 r·786.000 
7 5,160,000 3,680,000 5,520,000 1 0 ,960 '000 3 '940 ,000 0$70,000 
8 IS ,459,000 3,520,000 ~,507,000 4,310,000 8,536,000 7,980,000 
I 
9 !4 '903 ,000 4,026,000 ~,600,000 5,100,000 4,646,000 5,923,000 
10 5,276,000 4,145,~00 6,540,000 5,356,000 4,996,000 6,503,000 
11 r3 ,as3 ,ooo 2,990,000 ~,620,000 4,806,000~4,636,000 5,016,000 
I 
- 5,193,000 3,616,833 ~ '359 '166 5,368,444 5,126,000 6,192,555 
s 769,413.0 431,115.0 727,305.8 2,177,031 1,335,657 2,108,572 
52 5.9xlo10 I 1.8xlo10 5.3xlo10 4.7xlo11 1 . 8xl 011 4.4x1o11 
Mean values are recorded as erythrocytes per cubic millimeter of blood. 
T values revealed significant decreases of both acute and chronic Wild 
Type rabbits. In addition, T values demonstrated significant increases 
of both acute and chronic Tumorous head, as compared to the respective 
Wild Types and the chronic Tumorous head group and respect to the 
Control. Analysis of variance showed a significant increase of overall 
chronic mean with respect to overall acute mean. 
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Figure 7. Changes in mean erythrocyte count for Tuh, 
WT, and chronic studies. 
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The results of the thrombocyte count are shown in Table 9 and 
figure 8. Only chronic studies were performed using five rabbits in 
th~ Control groups, four rabbits in the WT groups, and six rabbits 
in the Tuh groups. Mean values and T tests (Table 5) indicate a 
marked increase in thrombocytes in the Tuh Group. A hyper-elevated 
501.2 J increase of Tuh compared with the Control groups and a 432.2% 
increase of Tuh compared with WT shows a thrombocytotic tendency. 
Analysis of variance was not applied to this assay. 
Table 10 and figure 9 show the results of leukocyte mean val-
ues. Leukocyte counts were taken from six rabbits in the acute Study 
and nine rabbits in the chronic Study. No significant changes were 
indicated by analysis of variance; however, a 19.4% leukocyte eleva-
tion can be seen from the overall acute mean to overall chronic 
mean (Appendix 2). These changes were indicated by T tests in Table 
5. They were a 15.2 increase for the acute Tuh Group compared with 
acute Controls, a 30.5 J increase for the chronic Tuh compared with 
chronic Controls, and a 30.5% increase for chronic Tuh compared with 
chronic WT. 
The results of the post-mortem inspections are summarized in 
Tables 11 and 12. 
The qualitative examination of the electrophoretic banding 
resolutions revealed no major consistent visual differences between 
the injected groups. 
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Table 9 
Mean Values of Thrombocyte Count for Both Acute and Chronic Assays 
- ACUTE CHRONIC 
An~r;noi C.ONTROL WI~D ~UEADRO S I WILD TUMO!(OUS o. TY E CONTROL TYPE HEAD 
I 
1 i - - -
2 I - - -
3 - - -
4 - - -
5 
- - -
6 - - 781,720 
I 
7 98,760 122 '180 346,720 
8 204,040 - 521 ,060 
9 64,840 93,720 360,060 
10 88,800 114,760 575,900 
11 66,060 154,120 557,060 
-X 104,500 121,195 523,770 
s 57,528.7 25,042.0 160,301 
52 ~309549600 '6 2 7103566 2 564671485 
Mean values are recorded as thrombocytes per cubic millimeter of blood. 
T values showed significant increases of chronic Tumorous head with 
respect to both chronic control and Wild Type. Analysis of variance 
was not applied. 
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Figure 8. Changes in mean plasma thrombocyte count for Tuh, 
WT , and Control animals in chronic studies. 
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Table 10 
Mean Values of Leukocytes for Both Acute and Chronic Assays 
ACUTE CHRONIC 
Animal CONTROL WI~D TUMQROUS WILD TUMQROUS no. I TV E HEAD CONTROL TYPE HEAD · 
1 - - - - - -
2 I - - - - - -
3 - - - 10 '1 00 9,009 15 '150 
4 - - - 7,501 9,509 9,926 
5 I - - - 7,344 7,962 9,730 
6 5,070 7,664 3,263 7,163 8,881 4,786 
7 6,000 9,034 10,600 13 '185 8,725 9,073 
8 5,717 8,804 6,945 7,655 9,023 12,962 
9 6,646 2,803 4,882 4,577 6,168 9,762 
10 4,788 I I 5,252 9,036 5,785 3,397 11,033 
11 6,584 6,413 5,381 6,821 4,704 9,092 
-
I 
X 5,081 I 6,662 6,685 7,792 7,486 10,168 
s 766.1 2,373 2,741 2,510 2,198 2,852 
52 586,860 15 ,6 3 2 ' 1 0 6 17, 516 ,666 6,302,277 lr4 ,834 ,839 8,139,119 
Mean values are recorded as leukocytes per cubic millimeter of blood. 
T values showed significant increases of both acute and chronic Tumor-
ous head with respect to the Controls and chronic Tumorous head as 
compared to chronic Wild Type. Analysis of variance revealed no sig-
nificance. 
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Figure 9. Changes in mean leukocyte count for Tuh, Wt, 
and Control animals in acute and chronic 
studies. 
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DISCUSSION 
The initial laboratory evaluation was designed to determine 
the mechanism utilized in reducing the bleeding times reported in 
Tuh injected rabbits. It appeared that these changes could have 
been influenced by vascular, platelet, or coagulation anomalies. 
Information concerning which processes may be involved were provided 
primarily by prothrombin times and platelet counts, although addi-
tional tests were performed to provide further information concern-
ing possible coagulation changes or other hematological alterations. 
The overall prothrombin times were significantly decreased 
from acute to chronically injected animals as shown by analysis of 
ariance. In addition, prothrombin times showed significant reduc-
tions from both acute WT and Tuh groups to chronic WT and Tuh, 
respectively {Table 5). These findings suggest a slight rate change 
of the extrinsic and common pathways, that is, Factors V, VII, X, 
prothrombin, and fibrinogen (see figure 2). In general, the clotting 
time is shortened as coagulant activity increases, and is detected 
by the appearance of fibrin threads. This relationship is such 
that small variations in clotting times represent major differences 
in activity when the times are of short duration. Compared to other 
coagulation test systems, the prothrombin test can have a more effi-
cient sensitivity because of its comparatively short time duration. 
The significant reduction of prothrombin times from acute WT and Tuh 
48 
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to chronic WT and Tuh rabbits does indicate increased overall 
activity of the extrinsic system. When activated prothrombin was 
added to plasma, the plasma Factor VII l'eacted with the tissue fac-
tor to form a reaction product which possibly accelerated the con-
version of Factor X to its activated form, Factor Xa. This, in turn, 
reacted with Factor V, calcium, and tissue phospholipid to form the 
extrinsic prothrombin activator that converted the prothrombin to 
thrombin. Thrombin then converted the fibrinogen to fibrin. The 
rate of fibrin formation is dependent on the concentration of the 
five extrinsic factors previously mentioned. This suggests a pos-
sible increased factor concentration in both WT and Tuh injected rab-
bits probably one or more of the reactions prior to Factor X forma-
tion due to their rate limiting nature. As seen in Table 6, the 
significant differences of prothrombin test mean values observed 
between both acute and chronic Tuh are greater than those for acute 
and chronic WT rabbits. This greater difference may be caused by 
the increased platelet factor concentration in the Tuh group (Table 
9). This factor concentration increase is possibly due to exces-
sive platelet thromboplastic function resulting from the observed 
thrombocytosis, that is, thrombocyte counts over 400,000/mm3 (Tables 
2 and 9). The possible acceleratory factors as aforementioned are 
platelet factors 1 through 4. These platelet constituents respec-
tively contribute 1) Factor V through the extrinsic system, 2) a 
clotting accelerating protein that further potentiates platelet 
aggregation and counteracts the inhibitory antithrombin III, 3) the 
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platelet phospholipid which accelerates blood coagulation by partic-
ipating in reactions involving Factor VIII and Factor V, 4) and the 
glycoprotein which further aids in accelerating coagulation (see 
pages 6 and 7). The increase of platelet phospholipid concentration 
in particular has the effect of concentrating the various coagula-
tion factors in a localized area, leading to faster reaction rates. 
An increase in serotonin released as a result of the high platelet 
concentration could have added vasoconstriction effects. 
Mean hematocrit values tended to remain about the same, reveal-
ing no major changes in blood viscosity. However, a slight eleva-
tion of the packed cell volume in chronic Tuh groups relative to 
acute Tuh groups was noted. The reason seems to be due to an 
increased red cell mass that could be associated with a slightly 
higher blood viscosity. 
Changes in mean hemoglobin values indicate significant fluctu-
ations between acute and chronic studies within the injected groups. 
The hemoglobin concentration in both the chronic WT and Tuh groups 
increased significantly over that of their respective acute study 
groups. There was also a significant overall increase in the mean 
erythrocyte count in the chronic study as compared to its acute 
study. This may represent a physiologic compensatory response to a 
tissue hypoxia indicated by the relatively low hemoglobin concentra-
tion in the acute rabbits. The elevation of erythrocytes appears 
to be a facilitated mutual adjustment so as to enhance oxygen 
transport, thus elevating the hemoglobin concentration. 
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Significant eythrocyte elevation in the chronic Tuh groups is 
consistent with the concomitant increase in hemoglobin concentration 
in that group. The erythrocyte content in both Tuh group studies 
was significantly greater than the respective WT group studies. It 
has been previously mentioned (page 12) that increased erythrocyte 
production is associated with increased thrombocyte production. 
Accelerated thrombopoiesis commonly is associated with accelerated 
erythropoiesis (49). 
There was no significant difference in the hemoglobin concen-
tration between the chronic WT and Tuh rabbits. However, there was 
a significant increase in red blood cell production by the Tuh 
injected rabbits. This rise in erythrocyte count in the chronic Tuh 
group was probably due to the proliferation of immature erythrocytes. 
The immature cells were probably those during the developmental per-
iod at which synthesis of hemoglobin is incomplete. Erslev and 
Gabuzda (60) note that the formation of hemoglobin begins at the 
earliest precursor stage of the developing erythroid cell and is 
completed when the anucleate reticulocyte matures to an erythrocyte. 
Synthesis begins just after the basophilic erythroblast stage. 
Leukocyte elevations were significant in both acute and 
chronic Tuh groups as compared to their Controls. These tests 
also revealed significant increases of chronic Tuh over chronic WT 
groups. Increases in both WT and Tuh groups are normal responses, 
probably due to an increase in the counter antigens. 
The data tend to support a reactive thrombocytotic mechanism 
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for increased platelet count especially the lack of any observed 
prolonged bleeding time (Table 2). Conclusive evidence of thrombo-
cytosis of the autonomous or reactive nature was not available 
because qualitative thrombocyte studies have not been performed. 
However, slight increases in erythrocytes and leukocytes, and the 
association of the injected tumor element (Table 2 and page 12) all 
give added credence to a reactive response. The homogenates may 
possibly accelerate thrombopoiesis which is also associated with 
accelerated erythropoiesis suggesting an interrelationship between 
erytnropoietic control mechanisms. Though little is known about the 
factors leading to accelerated platelet production in the various 
d1sorders associated with accelerated reactive platelet production, 
it is established that thrombopoietin does affect the number of 
megakar :ocytes found in the bone marrow and their proliferative 
behavior. As previously mentioned, such stimulation increases the 
rate of megakaryocyte maturation resulting from an increase in num-
ber of mitosis within the individual cells, and possibly an increase 
in the size of thrombocytes appearing in circulation. Thrombocyte 
turnover and production rate must be accelerated, yielding a total 
thrombocyte mass increase. Thrombocyte life-span or survival times 
usually are not affected by thrombocytosis further suggesting that 
the mechanism is over production rather than prolonged life-span. 
Post-mortem pathophysiologic analysis (67) revealed the 
absence of splenomegaly (Table 2). Thromboembolism or hemorrhage 
was not apparent. These facts coupled with relatively little 
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leukocyte increase, and concomitant increases in erythrocytes were 
evident. All these factors support reactive thrombocytotic tendency 
(Table 2). 
The more effective occlusion of the trauma site by the 
increased number of platelets could be an obvious explanation for 
any observed reduction in bleeding time. 
Autopsies were performed on 11 animals from each injection 
group. Post-mortem inspections indicated only four spleen discolor-
ations (two Tuh and two WT), two Wt injected rabbit liver discolor-
ations, and irregular indurated and purulent injection sites. There 
appeared to be little or no visual correlation between these discol-
orations, or the nature of injection sites as compared with abnormal 
cell counts or prothrombin times. Nothing conclusive can be derived 
from these findings. However, pathophysiologic analysis on three 
rabDit livers, one from each injection group, revealed aseptic cen-
trilobular hepatolysis in the Tuh rabbit specimen. Microscopic 
analysis showed central necrosis, large zones of hemorrhagic necro-
sis, and disappearance of cells. Spleens were normal. Injection 
sites, on biopsy, displayed no apparent abnormal cells (67). 
Future investigations should include thrombocyte qualitative 
functions such as platelet adhesive tests, platelet aggregation 
tests, platelet factor 3 availability tests, and bone marrow aspir-
ations. These tests will determine if the thrombocytosis is the 
reactive or autonomous type. Acquired qualitative thrombocyte 
defects have been described in all the myeloproliferative disorders 
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and cannot be ruled o~t even though the hemostatic effects of the 
thromocytes appear effective. The basic defect or defects which 
underlie the abnormalities in thrombocyte function in the myelopro-
-liferative syndromes remain to be determined. While these disorders 
have many features in common, the defects may not be identical in 
all cases. These functional defects usually involve aggregation, 
adhesion, and/ or secretion dysfunctions. 
SUMMARY 
The hemostatic mechanism of rabbits appeared to have been 
disturbed in response to tumorous-head Drosophila melanogaster 
antigens. 
The blood coagulation responses of two groups of rabbits, one 
group injected with wild-type Drosophila melanogaster and one group 
injected with a tumorous-head strain, had somewhat similar reduc-
tions in clotting times as compared to a control group. This indi-
cates that the tumorous-head injected animals do not appear to have 
a peculiar accelerated coagulation mechanism as compared with wild-
type injected animals. 
However, rabbits injected with tumorous-head antigens had a 
radical 5-fold elevation in plasma platelet concentration as com-
pared to rabbits injected with the wild-type antigens as well as 
control groups. This aids explanation for a previous speculated 
reduction in bleeding time as observed in the tumorous-head 
injected rabbits. The collected hematological data tend to be sup-
portive of a reactive thrombocytosis as compared with an autonomous 
reaction. The precise accelerated thrombokinetic mechanism for the 
excessively high increase in platelets remains for future investiga-
tions. 
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APPENDIX 1: STATISTICAL ANALYSIS 
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APPENDIX 1 
STATISTICAL ANALYSIS 
One of the procedures used to analyze the results of the var-
ious hematological assays was the unpaired 11 T11 test. The "T 11 test 
is used in the statistics of small samples with unknown standard 
deviations. The quantity t is given by the equation, 
where 
t = X - 1J 
srn 
x = Sample mean 
S = Standard deviation 
1..l = Population mean 
n = Number 
That is, t is the deviation of the estimated mean from that of the 
population, measured in tenns of s/ ln as the unit. 
The unpaired 11 T" test is a derivative of the "T" test and is 
used when the same individuals are not subjected to each treatment. 
In this case, the quantity t is given by the equation, 
t = ----
where 
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x1 = Mean of lst Group 
x2 = Mean of 2nd Group 
Sx = Standard error 
58 
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APPENDIX 2 
ANALYSIS OF VARIANCE 
Often a researcher can use a single experiment advantageously 
. 
to study two or more different kinds of treatment. Analysis of var-
iance rests on a separation of the variance of all the observations 
into parts, each of which measures variability attributable to some 
specific source. 
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